On Tuesday, William Blair initiated coverage on Kailera Therapeutics Inc. (NASDAQ:KLRA), the latest entrant in the fast-growing weight-loss drug market. The obesity-focused biotech raised more than $600 million in April through an initial public offering of 39.06 million shares priced at $16 each. Kailera Portfolio ‘Strongly Mirrors’ Eli Lilly William Blair analyst Andy Hsieh said Kailera’s obesity pipeline could position the company as a future challenger in the expanding weight-loss market, ci